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INTRODUCTION
Conventional teaching holds that an adult presenting
with a lateral neck lump has cancer until proven otherwise.
In fact, as many as 80% of such lesions are malignancies,
with the majority being metastatic deposits from a mucosal
squamous cell carcinoma. The incidence and patterns of
metastatic disease in the neck vary with the anatomical
site and T stage of the primary tumour. While most
cervical metastases are easily paired with a squamous cell
carcinoma of the upper aerodigestive tract, in 5% to 10%
of patients, no such primary tumour is immediately
apparent. If, after directed imaging and endoscopy, the
primary cancer is still not found, the patient is said to have
an unknown, or occult primary. This situation poses a
significant challenge to the treating clinician with regard
to subsequent work-up and treatment options. In the
following paper, the management of the occult primary is
discussed, along with a description of our institutional
experience.
PRESENTATION OF THE UNKNOWN PRIMARY
Patients presenting with metastatic squamous cell
carcinoma from an unknown primary show a male to
female preponderance of approximately 3:1 with an
average age between 60 and 70 years.1–9 Tobacco and
alcohol are thought to be individual and synergistic risk
factors, with an approximate 10 to 15-fold relative risk in
persons using significant amounts of each.10
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Typically, the cervical mass is painless, although pain
or compressive symptoms in adjacent structures may
occur.6,8 The delay in definitive diagnosis is usually
several months, as initial treatment with antibiotics often
precedes diagnosis.11 Metastatic nodes related to occult
primaries are most often unilateral, with bilateral disease
occurring in approximately 10% of patients.1,3,5,7,9,12 The
most common location for metastatic disease is level II
(30%–50%), with levels I and III less commonly involved
(10%–20%) and levels IV and V rarely affected (5%–
10%).1,3,7,12 Clinical and radiological evaluation
frequently identifies multiple involved nodes, although
in 10%–20% of patients, only a single node will be
present.1,3–9,12–14
CLINICAL EVALUATION
As most lateral neck masses in the adult are
malignancies, the clinical history should focus particular
attention on previously treated tumours and the likely
sites of an unrecognized primary cancer. The level of
metastatic involvement may give some clue as to the
likely primary site. A submandibular mass (level I) would
most commonly be related to a primary in the oral cavity
or skin. Level II nodes, including the jugulodigastric node,
may point to a primary in the oral cavity, oropharynx, or
supraglottic larynx. Middle and lower jugular nodes (levels
III and IV) are more likely related to a laryngeal or
hypopharyngeal cancer. Tumours of the nasopharynx
generally spread to level II or the posterior triangle, as well
as retropharyngeal nodes. Skin cancers are common
among fair-skinned elderly males and should always be
considered during history and physical examination.
Metastatic cutaneous malignancy may involve nodes in
the parotid tail, the pre-auricular region, level I, or the
posterior triangle. An often overlooked node frequently
affected by skin cancers is the external jugular node, lying
along the anterior border of the upper one-third of the
sternocleidomastoid muscle. Metastatic disease restricted
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to the supraclavicular region is often due to an in-
fraclavicular primary site.
All patients with a neck mass should undergo a
complete head and neck examination, which has been
greatly facilitated by the introduction of the flexible
nasopharyngoscope. Sites of particular importance are
the nasopharynx, tonsil, base of tongue and pyriform
sinuses, as these sites may harbour small occult primaries.
Palpation, especially for the base of tongue and tonsils, is
important, as these sites are often difficult to examine
even with appropriate equipment. The hypopharynx is
invariably difficult to examine outside the operating room,
but pooling of secretions may suggest a neoplasm in this
region. Lastly, a survey of the scalp and skin of the head
and neck should be routinely performed.
FINE NEEDLE ASPIRATION BIOPSY
Fine needle aspiration biopsy (FNAB) is well established
as the method of choice for tissue diagnosis in the
evaluation of a neck mass. Large series have shown that,
when done correctly, better than 95% of FNAB samples
will be adequate for diagnosis, with a 96% diagnostic
accuracy rate in the setting of squamous cell carcinoma.15
Additionally, the morbidity of FNAB is extremely low with
minimal contamination of surrounding tissues. Open
biopsy, on the other hand, requires an operation, with its
attendant morbidity. Additionally, it was previously thought
that an open biopsy might adversely affect prognosis, as
well as increase wound complications.16 Several series
have since suggested that this is not the case, with no
difference between open biopsy patients and matched
controls regarding survival, neck control, distant
metastases, or wound complications.17,18 Given its
convenience and accuracy, FNAB is preferred, with open
biopsy reserved for non-diagnostic FNABs or those cases
suspicious for lymphoma.
IMAGING
The choice and timing of imaging modalities vary
among institutions. Ideally, imaging studies should be
performed prior to any invasive procedure or treatment in
order to avoid artefact that might accompany these
interventions. For instance, biopsy of mucosal sites, and
certainly an open biopsy of a lymph node, might cause
local oedema or haematoma, making interpretation of
subsequent imaging studies difficult. FNAB causes minimal
distortion of local anatomy and can be performed prior to
imaging.
At most treatment centres, including our institution,
computed tomography (CT) scan is the imaging study of
choice. It is relatively inexpensive, readily available, and
yields excellent anatomical information. In almost all of
the reviewed series, CT was used preferentially, although
many of these series predated magnetic resonance imaging
(MRI).1,2,5–8,13,14,19,20 The scan should always be with
intravenous contrast, and most workers advocate that it
should include the region from skull base to clavicles.
Some authors recommended inclusion of the chest,
especially with low jugular or supraclavicular nodes.6
MRI provides soft-tissue definition generally superior
to that of the CT and is further enhanced with the use of
fat suppression techniques in T2 and postcontrast T1
images.21 These soft-tissue capabilities make MRI
especially useful for examination of the nasopharynx and
oropharynx.22 In fact, because these are common sites for
an occult primary, some advocate MRI as a first-line study
in that setting, with small case series showing a better
sensitivity than CT.23
Positron emission tomography (PET), a recently
developed imaging modality, also shows promise for the
detection of occult primary cancers. Anatomical definition
is poor, as for all nuclear medicine studies, but sensitivity
is fairly high.24 Hanasono et al reported a series in which
PET correctly identified 35% of primary tumours in patients
with a previously unknown primary, as compared to a
detection rate of 36% for MRI and 22% for CT scan.25
When a PET scan was combined with either a CT or MRI,
the detection rate increased to 40%.
EXAMINATION UNDER ANAESTHESIA
If history, physical examination and imaging have
failed to detect a primary tumour in a patient with metastatic
neck disease, the clinician should proceed with
examination under an aesthesia, including detailed
endoscopy. If the primary lesion is still not identified,
directed biopsies of likely mucosal primary sites should
be taken. Most authors advocate so-called ‘blind biopsies’
in this setting, although opinions differ on which sites
should be biopsied. It has been recommended that
nasopharynx, tongue base, tonsil and pyriform sinus
should all be biopsied ipsilateral to the affected node in
every case.5–9,14 Others recommend that biopsies should
be based on patterns of lymph node spread,3,13 or think
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that only macroscopically abnormal mucosa should be
biopsied.2 A mixed approach may also be reasonable,
with routine biopsies of the nasopharynx and tonsil, and
biopsies of pyriform sinus or tongue base only when the
mucosa appears abnormal.4,12 No study, to date, has
examined which strategy has the highest yield, but the
issue of tonsil biopsy has been examined. Several authors
have reported that only a complete tonsillectomy will
adequately sample the tonsil for malignancy, as small
tumours, on gross inspection, can go unnoticed in the
tonsillar crypts.26,27 At our institution, we routinely biopsy
the nasopharynx and usually perform a tonsillectomy
ipsilateral to the affected node. The tongue base and
pyriform sinus are biopsied only if a mucosal abnormality
is seen. It should be noted that, in our series of unknown
primary tumours, of the five patients who subsequently
manifested a primary cancer, none had biopsies of those
sites performed at initial endoscopy.1
Mention should also be made of new technologies
employing DNA probes and other genetic markers for the
identification of tumours. These methods allow for early
detection of malignant change on a molecular level prior
to any histopathological sign of cancer. Preliminary studies
have shown these techniques to be useful for the
identification of unknown primary tumours.28,29
TREATMENT
Surgery
Neck dissection is the standard initial treatment in the
setting of an unknown primary,1,2,4,12 the aim being to
encompass the clinically evident disease along with other
nodes at risk. A radical neck dissection removes nodal
tissues from levels I–V and sacrifices the spinal accessory
nerve, internal jugular vein, and sternocleidomastoid
muscle. A modified radical neck dissection spares one or
more of these structures but removes the same nodal
tissue. As there is no evidence that radical neck dissection,
is superior to modified radical neck dissection every
attempt should be made to preserve the spinal accessory
nerve, in order to reduce shoulder morbidity. While a
‘comprehensive’ neck dissection is probably the safest
oncological procedure, a role for selective neck dissection,
targeting specific nodal groups, is recognized. Patients
with clinical disease at levels IV or V could safely be
treated omitting level I. Similarly, if nodal disease is
limited to level I or II, a selective dissection encompassing
levels I through IV, but omitting level V, may be acceptable.
Though several series have included patients treated with
selective neck dissections, none has looked specifically at
outcome as a function of the extent of neck dissection.1–3
Therefore, there are no data to suggest that a selective
dissection, in combination with radiotherapy, is any more
or less effective than a comprehensive dissection in the
case of an unknown primary.
Radiation therapy – the ipsilateral neck
Radiation therapy is usually prescribed as adjunctive
treatment following the appropriate neck dissection. Most
would advocate a full course of radiation to the affected
neck if more than one node is involved or if extracapsular
spread or positive margins are present.1-3,12,30,31 For
pathologically proven N1 disease, radiation to the neck is
probably not warranted. Definitive neck irradiation,
reserving neck dissection for those with an incomplete
response, has also been described.5–7,14 This approach
may be equivalent to surgery with the clinically N1 neck,
but most authors agree that combined modality treatment
is needed with clinical N2 disease or greater.1–3,12,30–32 It
should also be pointed out that as many as one third of
patients with clinical N1 disease are found to have multiple
positive nodes when staged with a neck dissection.2 This
has obvious therapeutic and prognostic implications when
considering radiation as sole therapy for patients with
clinically early disease. With regard to the timing of neck
irradiation, postoperative radiation therapy is generally
preferred if combined modality treatment is planned, as
this reduces the risk of wound complications which may
be associated with preoperative radiation. For patients
with massive neck disease, preoperative radiation may be
used to decrease the dimensions of nodal disease, making
the subsequent neck dissection less difficult.
Radiation therapy – the contralateral neck
When both sides of the neck are clinically positive,
bilateral neck dissections should be carried out, followed
by bilateral radiation therapy. There is debate with regard
to the clinically negative contralateral neck. Reddy and
Marks showed that control of disease in the clinically
negative contralateral neck was 84% when both necks
were irradiated, compared to 45% when only the ipsilateral
neck was treated.5 In our own series, six of 37 patients
(16%) had recurrence in the contralateral neck and none
had received bilateral irradiation. The overall disease
control rate in the contralateral neck, however, was 84%,
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sites was, therefore, effective in treating the unknown
primary lesion. Interestingly, they also found that the field
and dose of radiation did not correlate with the incidence
or pattern of mucosal recurrence, casting some doubt on
their conclusion that the mucosal irradiation therapy had
a measurable effect.14
A major argument against full mucosal irradiation is
the substantial morbidity that follows treatment of the
mucosal sites, particularly xerostomia.1 Radiation to the
nasopharynx tends to have the most profound effect in
that regard. This, coupled with an inability to show any
improvement in outcome in our own series, has prompted
us to exclude the mucosa sites in the radiotherapy fields
unless there is bilateral neck disease, as this portends a
more aggressive tumour with a poor prognosis. However,
when there is a clinical suspicion of a specific, though
unproven, primary site, we will include radiation to that site.
Chemotherapy
Little has been written on the role of chemotherapy in
the case of the unknown primary. Cisplatin and 5-
fluorouracil (5-FU) have been used in varying
combinations. de Braud et al reported a higher complete
response rate and longer survival time with N3 disease
when chemotherapy was added to the treatment re-
gimen.9,13 The number of patients reviewed was small,
however, and the efficacy of chemotherapy, therefore,
remains unproven in this setting.
TREATMENT OUTCOME
Ipsilateral neck control rates vary among series between
42% and 90%.1–7,12,14,33 There is no apparent correlation
with treatment regimen, however, with similar results
reported for radiation and surgical therapies. The ipsilateral
neck control rate in our series was 89%, using primarily
Table. Treatment outcomes
Author n Ipsilateral Contralateral Appearance Distant Disease-specific
control control of primary metastases survival
McMahon1 37 89% 84% 14% 5% 63% at 4 years
Davidson2 73 74% NR 12% 21% 60% at 5 years
Harper14 69 77% NR 12% NR 60% at 5 years
Maulard4 113 86% NR 10% 16% 38% at 5 years
NR = not recorded.
identical to the results of Reddy et al using bilateral
irradiation. Treating the clinically negative neck with
radiation also contravenes a basic rule that applies to any
form of elective neck treatment. That is, it is not appropriate
to electively treat the neck if the primary is not controlled.
Contralateral irradiation is appropriate, therefore, if
radiotherapy is also to be directed at the mucosal sites
with a view to definitively treating the occult primary. We,
therefore, reserve contralateral neck irradiation for cases
of bilateral neck disease or those with a high suspicion of
a nasopharyngeal primary.1
Radiation therapy – mucosal sites
Contralateral neck failure indicates the presence of
active and, most likely, progressive mucosal disease.
Failure in the contralateral neck should, therefore, prompt
a thorough reevaluation of the patient, including focused
physical examination, imaging, and endoscopy.
A principal area of controversy is whether or not to
irradiate the mucosa, particularly the regions thought
most often to harbor the occult primary lesion, i.e.
nasopharynx, base of tongue, tonsil, and pyriform sinus.
Opinions in the literature are divided, with similar results
reported by those who include these sites and those who
do not. Reddy and Marks reported that the likelihood of
mucosal recurrence decreased significantly, if these
mucosal sites were included in the radiation ports.5
Similarly, Davidson et al found that mucosal recurrence
declined with the inclusion of possible primary sites in the
radiation fields as compared to earlier series in which this
comprehensive radiation therapy was not routine.2 Harper
et al reported that the subsequent appearance of a primary
cancer after neck and mucosal site irradiation was similar
to the rate of metachronous second primaries following
definitive radiation for known primary tumours.14 They
concluded that directing radiation to the neck and mucosal
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a surgical approach with adjuvant irradiation reserved for
N2 disease or greater. As previously stated, contralateral
neck control varies between 80% and 90%.1,5 A summary
of outcomes is shown in the Table.
A primary site is eventually discovered in 10% to 30%
of patients presenting with an occult primary cancer.12,14,33
Generally, this occurs within 2 years of treatment, although
later development of a primary has been described. It may
be difficult to distinguish between the true unknown
primary and an incidental second primary, the latter
having an incidence of 3% per year following treatment
of an initial primary lesion. In our own series, 5 of 37
patients (14%) eventually manifested a primary tumour.
The most common primary sites, again, are the
nasopharynx, base of tongue, tonsil, and pyriform sinus.
Special mention should be made of level IV and specifically
supraclavicular nodes, as these are associated with a
primary in the chest in up to 30% of cases.13
Distant metastases are discovered in 5% to 40% of
patients, usually within 2 years of treatment.1–5,7 The most
common sites are the lung and bone. Liver metastases also
occasionally develop. There appears to be some correlation
between the likelihood of distant spread and the stage of
disease at presentation.
Disease-specific survival rates vary between 33% and
66% at 5 years.1–7,14,33 Poor prognostic indicators include
extracapsular spread, positive margins, and extent of
disease at presentation.1,2 Survival in our series was 63%
at 4 years.
OVERALL TREATMENT APPROACH
Our approach to the unknown primary begins with a
thorough history and physical examination including
nasopharyngoscopy and directed palpation of the mucosal
sites. A survey for skin lesions on the head and neck is also
performed. The neck mass is then sampled using FNAB to
give a histological diagnosis. The imaging study of choice
is CT, with the PET scan under investigation and MRI
reserved for difficult cases and patients with contrast
allergy. Each patient then undergoes panendoscopy,
including direct laryngoscopy and oesophagoscopy. The
nasopharynx is routinely biopsied and the ipsilateral
tonsil removed. Mucosa at the base of the tongue or
hypopharynx is biopsied only if abnormal in appearance.
At the same operation, a neck dissection to encompass the
clinical disease and adjacent at-risk nodes is performed,
with bilateral dissection as needed for bilateral disease. If
the neck is pathologically N1, no further treatment is
given. For N2 disease or greater, the ipsilateral neck is
irradiated. If both sides of the neck are pathologically
positive, or if there is a suspicion of a nasopharyngeal
primary, both sides of the neck are irradiated along with
the likely mucosal sites. Finally, the patient will be
monitored closely for the next 5 years to check for the
subsequent appearance of a primary cancer.
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